2019
61st ASH Annual Meeting & Exposition, Orlando, FL, US
A Quantitative Systems Pharmacology (QSP) Model to Predict Receptor Occupancy of Bruton’s Tyrosine Kinase (BTK) Inhibitors in Peripheral Blood Mononuclear Cells, Bone Marrow and Lymph Nodes of Patients with B-Cell Malignancies
Authors: Srikumar Sahasranaman1, Oleg Demin Jr2, Dmitry Shchelokov2, Veronika Musatova2, Nageshwar Budha1, Ying Ou2
Affiliation: 1Clinical Pharmacology, BeiGene USA, Inc.; 2InSysBio, Moscow, Russia
ACoP10, Orlando, FL, US
AD pathology QSP platform: studying the interactions between different toxicity modules through the junction of mechanistic submodels
Authors: Tatiana Karelina
Physiologically based pharmacokinetic and receptor occupancy (PBPK/RO) modeling of anti-PD1 monoclonal antibodies
Authors: Oleg Demin Jr, Dmitry Shchelokov
Investigation of bell-shaped dose response of bispecific T-cell engaging antibodies under physiological conditions
Authors: Oleg Demin Jr
Quantitative systems pharmacology model of COPD progression with implemented standard of care treatments (LABA/ICS)
Authors: Galina Lebedeva1, Mikhail Benkov1, Oleg Demin1, Loveleena Bansal2, Cibele Falkenberg2, Martin Hingle3, Valeriu Damian2
Affiliation: 1InSysBio, Moscow, Russia; 2GSK, Collegeville, PA; 3GSK, Stevenage, UK
LikelihoodProfiler is a software package for practical identifiability analysis for the large-scale dynamic models
Authors: Ivan Borisov, Evgeny Metelkin
Development of quantitative systems pharmacology (QSP) model of systemic lupus erythematosus and its application to explore possible mechanisms of alterations in serum IFN1 resulting from anti-IFNAR1 treatment
Authors: Sergey Smirnov1, Alexsandra Diakonova1, Oleg Demin1, Christopher Morehouse2, Dominic Sinibaldi2, Raj Tummala3, Denison Kuruvilla4, Yen Len Chia4, Lorin K. Roskos2, Wendy I. White2
Affiliation: 1InSysBio, Moscow, Russia; 2MedImmune, Gaithersburg, MD USA; 3AstraZeneca Gaithersburg, MD USA; 4MedImmune, San Francisco, CA USA
Influence of neuronal protein degradation pathways on tau pathology studied by Quantitative Systems Pharmacology model
Authors: Mark Meerson1, Tatiana Karelina1 and Diana Сlausznitzer2
Affiliation: 1InSysBio, Moscow, Russia; 2AbbVie, Ludwigshaven, Germany
From stem cell to erythrocyte and platelet: QSP model of erythropoiesis and thrombopoiesis for assessing the impact of pharmacological interventions
Authors: Alexander Stepanov, Galina Lebedeva
Workflow for development of QSP models of Immune Response requires appropriate software infrastructure
Authors: Tatiana Karelina, Sergey Smirnov, Galina Lebedeva, Oleg Demin Jr, Evgeny Metelkin, Nail Gizzatkulov
’Heta’ is a new declarative language to define the large-scale systems pharmacology and systems biology models
Authors: Evgeny Metelkin
PBPK modeling for therapeutic nanoparticles loaded with drug: distribution and release
Authors: Evgeny Metelkin, Oleg Demin
In vitro to in vivo extrapolation of CD4 T cell polarization in lymph nodes using QSP modeling
Authors: Oleg Demin, Svetlana Rubina, Dmitry Shchelokov, Oleg Demin Jr
QSP model of human granulopoiesis and neutrophil homeostasis for assessment of pharmacological interventions
Authors: Galina Lebedeva, Alexander Stepanov
SITC 2019, National Harbor, MD, US
Prediction of target occupancy in tumor after treatment with anti-PD1 antibodies using physiologically based pharmacokinetic modeling
Authors: Oleg Demin Jr, Dmitry Shchelokov
Quantitative systems pharmacology modeling of B-cell acute lymphoblastic leukemia treatment with bispecific T-cell engaging antibodies for investigation of bell-shaped dose response
Authors: Oleg Demin Jr
PEGS 2019, Boston, MA, US
Selection of First-in-Human Study Dose for Antibodies and Antibody Constructs Using Quantitative Systems Pharmacology Modeling
Authors: Oleg Demin Jr, Dmitry Shchelokov
PAGE 2019, Stockholm, Sweden
Quantitative Systems Pharmacology model of key intraneuronal pathways regulating toxic protein accumulation
Authors: Mark Meerson1, Tatiana Karelina1 and Diana Сlausznitzer2
Affiliation: 1InSysBio, Moscow, Russia, 2AbbVie, Ludwigshaven, Germany
Physiologically based pharmacokinetic modeling of anti-PD-1 therapeutic antibodies
Authors: Dmitry Shchelokov, Oleg Demin Jr
Amyloid ? in vitro prion properties and in vivo pathology exacerbation mechanisms studied by translation quantitative systems pharmacology model for prediction of anti-protofibril immunotherapy effects
Authors: Tatiana Karelina
Application of different approaches to generate virtual patient populations for QSP model of physiologically based pharmacokinetic model of anti-PD-1 therapeutic antibodies
Authors: Galina Kolesova, Oleg Demin, Evgeny Metelkin and Dmitry Shchelokov
First
Prev